7

Reply:

Year:
2008
Language:
english
File:
PDF, 51 KB
english, 2008
8

Reply:

Year:
2009
Language:
english
File:
PDF, 56 KB
english, 2009
9

Reply:

Year:
2009
Language:
english
File:
PDF, 41 KB
english, 2009
11

Reply: Fibrosis in liver as a predictive marker for hepatitis C virus therapy

Year:
2010
Language:
english
File:
PDF, 168 KB
english, 2010
12

Reply:

Year:
2010
Language:
english
File:
PDF, 494 KB
english, 2010
15

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients

Year:
2011
Language:
english
File:
PDF, 155 KB
english, 2011
16

Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?

Year:
2012
Language:
english
File:
PDF, 793 KB
english, 2012
22

Reply

Year:
2013
Language:
english
File:
PDF, 298 KB
english, 2013
24

How to optimize HCV therapy in genotype 1 patients: predictors of response

Year:
2013
Language:
english
File:
PDF, 173 KB
english, 2013
36

Benefits of dietary short-chain triglycerides

Year:
1992
Language:
english
File:
PDF, 147 KB
english, 1992
37

Table of Contents Vol. 4, No. 2, 2004

Year:
2004
File:
PDF, 93 KB
2004
43

Current and future HCV therapy: do we still need other anti-HCV drugs?

Year:
2015
Language:
english
File:
PDF, 225 KB
english, 2015
48

Características histopatológicas do enfisema pulmonar em modelo experimental

Year:
2014
Language:
english
File:
PDF, 404 KB
english, 2014
50

Response to Dr. Sertoglu and Colleagues

Year:
2015
Language:
english
File:
PDF, 1.16 MB
english, 2015